Quarter
Charts

IMMIX BIOPHARMA, INC.

IMMX

CIK 0001873835 · Quarterly mode · latest period FY2022 (Q4) (ending 2022-12-08) · sourced from SEC EDGAR

At a glance · FY2022 (Q4)

Revenue
$20M
Operating Income
$20M
Net Income
$20M
Gross Profit
$20M

Quality Score

Quality score

6-dimension fundamental snapshot · latest annual filed values · S&P 500 calibration

Poor
17/100
  • Profitability
    0ROIC -44.2% (10% = solid, 20%+ = moat)
  • Liquidity
    100Current Ratio 10.01 (above 1.5 = solid)
  • Leverage
    0Insufficient data
  • Efficiency
    0Insufficient data
  • Growth
    0Insufficient data
  • Margin Trend
    0Insufficient data

Calibrated to S&P 500 medians. Each sub-score is computed from a single CFA-grade ratio (Profitability = ROIC, Liquidity = Current Ratio, Leverage = D/E, Efficiency = Asset Turnover, Growth = Revenue YoY, Margin Trend = 4Q operating-margin avg vs prior 4Q). Overall = simple mean.

Capital allocation · trailing 4 quarters

how the company spent its cash
Capex (TTM)
$733K
investment in PP&E
Stock buybacks (TTM)
—
share count reduction
Stock-based comp (TTM)
$2M
non-cash dilution

Balance sheet · 2025-12-31

latest filed snapshot
Total assets
$105M
everything owned
Total liabilities
$11M
everything owed
Stockholders' equity
$94M
shareholder claim

Recent performance · 21 quarters

Revenue
$20M
Net Income↓-6.1% -$436K
$-8M
Free Cash Flow↑+67.4% +$342K
$-165K

Drill down

IMMX Sankey

See IMMIX BIOPHARMA, INC.'s revenue flow into every line item of the income statement and balance sheet — every dollar accounted for, with prior-period comparison.

Open Sankey

IMMX Charts

21 quarters of historical line items — Income, Cash Flow, Balance Sheet, plus margins. Click any chart for the trend dialog.

Open Charts

IMMX Key Metrics

EPS, BVPS, FCF/Share, ROE, ROA, ROIC, D/E, Current Ratio, Quick Ratio, Asset Turnover — 10 CFA-grade fundamentals derived from EDGAR data.

Open Key Metrics